An Indiana-based pharmaceutical firm announced Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among long-term care facility residents and staff.
Eli Lilly and Company confirmed the Phase 3 BLAZE-2 COVID-19 prevention trial results suggest that residents randomized to bamlanivimab have up to an 80 percent lower risk of contracting COVID-19 versus residents in the same facility randomized to placebo.
Neutralizing Antibody Reduced COVID-19 Risk by 80% at Nursing Homes
Japan Launches Early Study of Moderna’s COVID-19 Vaccine
A Massachusetts-based biotechnology company pioneering messenger RNA (mRNA) vaccines announced that the first participant was recently dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 in Japan.
Moderna, Inc confirmed this clinical trial is led by Takeda Pharmaceutical Co., based in Osaka, Japan.
TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate, known as mRNA-1273.
Tocilizumab Does Not Improve Outcomes in Severe COVID-19
Tocilizumab plus standard care no better for improving clinical outcomes at 15 days and may increase mortality
Mortality Decreased for COVID-19 ICU Patients Over Time
Mortality decreased from 43.5 to 19.2 percent between first and last 15-day periods; no change seen in other patient factors
President Biden Unveils Details of National Pandemic Response Plan
On Wednesday, Biden signed three executive orders relating to the coronavirus pandemic shortly after taking office
Hahn Resigns as Head of FDA, Dr. Janet Woodcock New Interim Chief
A permanent FDA commissioner has not yet been nominated, but Woodcock is under consideration